Sessile serrated colon
adenoma/
polyps (SSA/P) are found during routine screening colonoscopy and may account for 20% to 30% of
colon cancers. However, differentiating SSA/Ps from hyperplastic
polyps (HP) with little risk of
cancer is challenging and complementary molecular markers are needed. In addition, the molecular mechanisms of
colon cancer development from SSA/Ps are poorly understood.
RNA sequencing (
RNA-Seq) was performed on 21 SSA/Ps, 10
HPs, 10 adenomas, 21 uninvolved colon, and 20 control colon specimens. Differential expression and leave-one-out cross-validation methods were used to define a unique gene signature of SSA/Ps. Our SSA/P gene signature was evaluated in
colon cancer RNA-Seq data from The
Cancer Genome Atlas (TCGA) to identify a subtype of
colon cancers that may develop from SSA/Ps. A total of 1,422 differentially expressed genes were found in SSA/Ps relative to controls. Serrated polyposis syndrome (n = 12) and sporadic SSA/Ps (n = 9) exhibited almost complete (96%) gene overlap. A 51-gene panel in SSA/P showed similar expression in a subset of TCGA
colon cancers with high
microsatellite instability. A smaller 7-gene panel showed high sensitivity and specificity in identifying BRAF-mutant, CpG island methylator phenotype high, and MLH1-silenced
colon cancers. We describe a unique gene signature in SSA/Ps that identifies a subset of
colon cancers likely to develop through the serrated pathway. These gene panels may be utilized for improved differentiation of SSA/Ps from HPs and provide insights into novel molecular pathways altered in
colon cancer arising from the serrated pathway.
Cancer Prev Res; 9(6); 456-65. ©2016 AACR.